UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 219

Sortiert nach

Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2015-12, Vol.386 (10011), p.2404-2412

2015

Volltextzugriff (PDF)

Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level

World psychiatry, 2011-06, Vol.10 (2), p.138-151

2011

Volltextzugriff (PDF)

The Metabolic Effects of Antipsychotic Medications

Canadian journal of psychiatry, 2006-07, Vol.51 (8), p.480-491

2006

Volltextzugriff (PDF)

Utilization of the Behavior Change Wheel framework to develop a model to improve cardiometabolic screening for people with severe mental illness

Implementation science : IS, 2017-11, Vol.12 (1), p.134-134, Article 134

2017

Volltextzugriff (PDF)

Metabolic Screening After the American Diabetes Association's Consensus Statement on Antipsychotic Drugs and Diabetes

Diabetes care, 2009-06, Vol.32 (6), p.1037-1042

2009

Volltextzugriff (PDF)

Antipsychotic medications: metabolic and cardiovascular risk

The journal of clinical psychiatry, 2007, Vol.68 Suppl 4, p.8

Newcomer, John W

2007

Volltextzugriff (PDF)

Metabolic considerations in the use of antipsychotic medications: a review of recent evidence

The journal of clinical psychiatry, 2007, Vol.68 Suppl 1, p.20

Newcomer, John W

2007

Volltextzugriff (PDF)

CRANIUM: a quasi-experimental study to improve metabolic screening and HIV testing in community mental health clinics compared to usual care

BMC psychiatry, 2022-11, Vol.22 (1), p.687-687, Article 687

2022

Volltextzugriff (PDF)

Are the cardiometabolic complications of schizophrenia still neglected?: barriers to care [Paper in supplement: Pathways to Schizophrenia: a New Wave of Prevention and Early Intervention Strategies]

Medical journal of Australia, 2009-02, Vol.190 (4 Supplement), p.S39-S42

2009

Volltextzugriff (PDF)

Association of C-reactive protein and metabolic risk with cognitive effects of lurasidone in patients with schizophrenia

Comprehensive psychiatry, 2020-10, Vol.102, p.152195, Article 152195

2020

Volltextzugriff (PDF)

Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysis

BMC health services research, 2018-04, Vol.18 (1), p.243-243, Article 243

2018

Volltextzugriff (PDF)

Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review

CNS drugs, 2005, Vol.19 (1), p.1-93

NEWCOMER, John W

2005

Volltextzugriff (PDF)

Memantine for late-life depression and apathy after a disabling medical event: a 12-week, double-blind placebo-controlled pilot study

International journal of geriatric psychiatry, 2012-09, Vol.27 (9), p.974-980

2012

Volltextzugriff (PDF)

Revisiting diabetes risk of olanzapine versus aripiprazole in serious mental illness care

BJPsych open, 2024-08, Vol.10 (5), p.e144, Article e144

2024

Volltextzugriff (PDF)

Diabetes and Cardiovascular Care Among People with Severe Mental Illness: A Literature Review

Journal of general internal medicine : JGIM, 2016-09, Vol.31 (9), p.1083-1091

2016

Volltextzugriff (PDF)

Metabolic syndrome and mental illness

The American journal of managed care, 2007-11, Vol.13 (7 Suppl), p.S170-S177

Newcomer, John W

2007

Volltextzugriff (PDF)

4.20 ADIPONECTIN AND ADIPOSITY CHANGE DURING INITIAL ANTIPSYCHOTIC EXPOSURE IN YOUTH

Journal of the American Academy of Child and Adolescent Psychiatry, 2016-10, Vol.55 (10), p.S169-S169

2016

Volltextzugriff (PDF)

Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study

The American journal of psychiatry, 2020-12, Vol.177 (12), p.1168-1178

2020

Volltextzugriff (PDF)

Severe mental illness and risk of cardiovascular disease

JAMA : the journal of the American Medical Association, 2007-10, Vol.298 (15), p.1794

2007

Volltextzugriff (PDF)

Use of an Interactive Obesity Treatment Approach in Individuals With Severe Mental Illness: Feasibility, Acceptability, and Proposed Engagement Criteria

JMIR formative research, 2022-12, Vol.6 (12), p.e38496-e38496

2022

Volltextzugriff (PDF)

Using Innovation-Corps (I-Corps™) Methods to Adapt a Mobile Health (mHealth) Obesity Treatment for Community Mental Health Settings

Frontiers in digital health, 2022-05, Vol.4, p.835002-835002

2022

Volltextzugriff (PDF)

Antidepressant Drug Compliance: Reduced Risk of MI and Mortality in Depressed Patients

The American journal of medicine, 2011-04, Vol.124 (4), p.318-324

2011

Volltextzugriff (PDF)

Medical risk in patients with bipolar disorder and schizophrenia

The journal of clinical psychiatry, 2006, Vol.67 Suppl 9, p.25

Newcomer, John W

2006

Volltextzugriff (PDF)

Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose?

BMC psychiatry, 2011-12, Vol.11 (1), p.197-197, Article 197

2011

Volltextzugriff (PDF)

Lurasidone and risk of metabolic syndrome: results from short and long-term studies in patients with bipolar depression

CNS spectrums, 2023-12, Vol.28 (6), p.680-687

2023

Volltextzugriff (PDF)

1 – 25 von 219

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(199)
Mit Volltextzugriff
(162)

Publikationsform

Sprache

Englisch
(219)
Japanisch
(14)

Erscheinungsjahr

n.n

Thema

Science & Technology
(143)
Life Sciences & Biomedicine
(141)
Humans
(133)
Psychiatry
(100)
Male
(75)
Female
(65)
Adult
(60)
Biological And Medical Sciences
(54)
Medical Sciences
(51)
Antipsychotic Agents - Therapeutic Use
(47)
Middle Aged
(46)
Antipsychotic Agents - Adverse Effects
(45)
Schizophrenia - Drug Therapy
(44)
Psychology. Psychoanalysis. Psychiatry
(41)
Schizophrenia
(36)
Aged
(30)
Risk Factors
(30)
Psychopathology. Psychiatry
(27)
Diabetes
(26)
Antipsychotics
(25)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial

Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level

The Metabolic Effects of Antipsychotic Medications

Utilization of the Behavior Change Wheel framework to develop a model to improve cardiometabolic screening for people with severe mental illness

Metabolic Screening After the American Diabetes Association's Consensus Statement on Antipsychotic Drugs and Diabetes

Antipsychotic medications: metabolic and cardiovascular risk

Metabolic considerations in the use of antipsychotic medications: a review of recent evidence

CRANIUM: a quasi-experimental study to improve metabolic screening and HIV testing in community mental health clinics compared to usual care

Are the cardiometabolic complications of schizophrenia still neglected?: barriers to care [Paper in supplement: Pathways to Schizophrenia: a New Wave of Prevention and Early Intervention Strategies]

Association of C-reactive protein and metabolic risk with cognitive effects of lurasidone in patients with schizophrenia

Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysis

Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review

Memantine for late-life depression and apathy after a disabling medical event: a 12-week, double-blind placebo-controlled pilot study

Revisiting diabetes risk of olanzapine versus aripiprazole in serious mental illness care

Diabetes and Cardiovascular Care Among People with Severe Mental Illness: A Literature Review

Metabolic syndrome and mental illness

4.20 ADIPONECTIN AND ADIPOSITY CHANGE DURING INITIAL ANTIPSYCHOTIC EXPOSURE IN YOUTH

Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study

Severe mental illness and risk of cardiovascular disease

Use of an Interactive Obesity Treatment Approach in Individuals With Severe Mental Illness: Feasibility, Acceptability, and Proposed Engagement Criteria

Using Innovation-Corps (I-Corps™) Methods to Adapt a Mobile Health (mHealth) Obesity Treatment for Community Mental Health Settings

Antidepressant Drug Compliance: Reduced Risk of MI and Mortality in Depressed Patients

Medical risk in patients with bipolar disorder and schizophrenia

Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose?

Lurasidone and risk of metabolic syndrome: results from short and long-term studies in patients with bipolar depression

Suchergebnisse filtern